Shares of Threshold Pharmaceuticals Inc. lost more than half their value after the company said it was dropping its benign prostatic hyperplasia drug, TH-070, following misses in Phase II and Phase III studies. (BioWorld Today)
Shares of Threshold Pharmaceuticals Inc. lost more than half their value after the company said it was dropping its benign prostatic hyperplasia drug, TH-070, following misses in Phase II and Phase III studies. (BioWorld Today)
ConjuChem Biotechnologies Inc. discontinued dosing in a Phase II trial of its growth hormone product, DAC:GRF in HIV lipodystrophy, pending an investigation into the death of a patient. (BioWorld Today)
ConjuChem Biotechnologies Inc. discontinued dosing in a Phase II trial of its growth hormone product, DAC:GRF in HIV lipodystrophy, pending an investigation into the death of a patient. (BioWorld Today)
In one of its largest deals to date, Archemix Corp. partnered with Irish firm Elan Corp. plc to develop up to three aptamer-based drugs against autoimmune inflammatory disease and could earn more than $350 million in potential milestones. (BioWorld Today)
In one of its largest deals to date, Archemix Corp. partnered with Irish firm Elan Corp. plc to develop up to three aptamer-based drugs against autoimmune inflammatory disease and could earn more than $350 million in potential milestones. (BioWorld Today)
